For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Aflac Inc. (AFL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -23 (−100…+100 Quality+Value blend) · Quality 21 · Value -59 · Sentiment -57 (timing only, not weighted) · Composite fair value $101.10 vs $121.45 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Aflac Inc.
AFL NYSEAflac Inc. is a financial services holding company specializing in supplemental health and life insurance. The company primarily operates through two segments, Aflac Japan and Aflac U.S., providing insurance products that help policyholders manage out-of-pocket costs not fully covered by primary medical plans. Aflac is best known for its supplemental policies, including cancer insurance, accident coverage, critical illness plans, hospital indemnity, disability, and long-term care offerings. These products are marketed largely through independent agents and brokers, with a strong presence in worksite distribution, where policies are offered to employees through their employers, as well as through digital and direct-to-consumer channels. Headquartered in Columbus, Georgia, Aflac serves individuals and businesses, playing a notable role in the insurance market by focusing on financial protection against unexpected health-related expenses in both the United States and Japan.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.82
Total Equity: $29.49B
Shares: 534,604,106
Total Debt: $0.00
Cash: $6.25B
EBITDA: N/A
Total Debt: $0.00
Cash: $6.25B
Revenue: $17.36B
Revenue: $17.36B
Revenue: $17.36B
Total Equity: $29.49B
Tax Rate: 19.6%
Equity: $29.49B
Total Debt: $0.00
Cash: $6.25B
Current Liabilities: N/A
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $29.49B
Shares: 534,604,106
Shares: 534,604,106
CapEx: $0.00
Shares: 534,604,106
Stock Price: $121.45
Net Income: $3.65B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 17, 2026 12:39am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $21.5B | $19.2B | $18.8B | $19.1B | $17.4B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | -$8.0M | $11.0M | $140.0M | $201.0M | $191.0M |
| Operating Income | — | — | — | — | — |
| Net Income | $4.2B | $4.4B | $4.7B | $5.4B | $3.6B |
| EBITDA | — | — | — | — | — |
| EPS | $6.42 | $6.96 | $7.81 | $9.68 | $6.84 |
| EPS (Diluted) | $6.39 | $6.93 | $7.78 | $9.63 | $6.82 |
Balance Sheet (Annual)
Last updated: Aug 17, 2026 12:20am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.1B | $3.9B | $4.3B | $6.2B | $6.2B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $157.5B | $131.0B | $126.7B | $117.6B | $116.5B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $124.3B | $108.7B | $104.7B | $91.5B | $87.0B |
| Total Equity | $33.3B | $22.4B | $22.0B | $26.1B | $29.5B |
| Retained Earnings | $41.4B | $44.6B | $48.0B | $52.3B | $54.7B |
Cash Flow (Annual)
Last updated: Aug 17, 2026 12:39am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $5.1B | $3.9B | $3.2B | $2.7B | $2.6B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | -$700.0M | -$1.4B | $0 | -$194.0M | -$84.0M |
| Dividends Paid | -$855.0M | -$979.0M | -$966.0M | -$1.1B | -$1.2B |
| Stock Buybacks | -$2.3B | -$2.4B | -$2.8B | -$2.8B | -$3.5B |
| Net Change in Cash | -$90.0M | -$1.1B | $363.0M | $1.9B | $16.0M |
Growth Trends (YoY %)
Last updated: Aug 17, 2026 12:39am (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -11.1% | -1.6% | +1.5% | -9.3% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | +4.4% | +5.5% | +16.8% | -33.0% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 11, 2026 12:36pm (12d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-20 | $0.61 | — | — | — |
| 2026-02-18 | $0.61 | — | — | — |
| 2025-11-19 | $0.58 | — | — | — |
| 2025-08-20 | $0.58 | — | — | — |
| 2025-05-21 | $0.58 | — | — | — |
| 2025-02-19 | $0.58 | — | — | — |
| 2024-11-20 | $0.50 | — | — | — |
| 2024-08-21 | $0.50 | — | — | — |
| 2024-05-21 | $0.50 | — | — | — |
| 2024-02-20 | $0.50 | — | — | — |
| 2023-11-14 | $0.42 | — | — | — |
| 2023-08-22 | $0.42 | — | — | — |
| 2023-05-16 | $0.42 | — | — | — |
| 2023-02-14 | $0.42 | — | — | — |
| 2022-11-15 | $0.40 | — | — | — |
| 2022-08-23 | $0.40 | — | — | — |
| 2022-05-17 | $0.40 | — | — | — |
| 2022-02-15 | $0.40 | — | — | — |
| 2021-11-16 | $0.33 | — | — | — |
| 2021-08-17 | $0.33 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-17Aflac's cost base is dominated by claims adjudication, policy administration, agent support and Japan back-office work — exactly the paperwork AI compresses — while premium rates are set by filings and competitive positioning, not by delivery cost, so expense-ratio savings can drop to the bottom line.
Supplemental products are lightly underwritten and price-comparable; AI-mediated benefits enrollment and consumer-side health risk assessment can both commoditize the shelf slot and tilt who buys cancer/critical-illness cover, pressuring morbidity margins Aflac cannot reprice quickly in Japan.
Whether Aflac's distribution (US worksite/broker, Japan Post and bank channels) remains the gateway or becomes a commoditized supplier behind AI enrollment platforms — observable in US new annualized premium sales per broker channel and Japan third-sector new policy counts.
Regulated insurance capital and reserves, decades of Japanese third-sector morbidity experience, the Japan Post/bank and US payroll-deduction distribution rails, and a consumer brand that sells a low-ticket discretionary product at the worksite.
AI Lens thesis
Aflac sells a promise backed by regulated capital, not an information service, so AI reaches it mainly through the cost side and the distribution layer: claims automation, underwriting triage, multilingual service and agent productivity lower unit administrative cost on a fixed-price contract, which is margin-accretive; the risk is not that AI writes better cancer policies but that AI agents sitting between employers, brokers and carriers turn supplemental cover into a price-shopped commodity, and that cheaper individual risk prediction sharpens adverse selection in simplified-issue products; neither mechanism explains the recent revenue decline, which is currency, pricing discipline and persistency, not AI.
What the market may be underestimating
Upside Japan back-office and claims labor is expensive and shrinking demographically — AI-driven administration is a way to hold Japan margins as the in-force block runs off, an offset the market treats purely as population decline.
Downside If AI-native benefits platforms own the enrollment interface, Aflac becomes a rate on someone else's screen; that squeezes commission economics and its most valuable asset — payroll-deduction access — without any obvious quarter where it shows up.
Outcome range spread 32
Growth Outlook
Analyzed 2026-08-17 16:20The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw quarterly tape first: revenue went $2.95B → $5.40B → $3.40B → $4.16B → $4.74B → $4.87B → $4.35B → $4.12B, and net income swung from -$93M to $1.9B to $29M to $1.64B. That's not an operating business trajectory — that's insurance accounting with investment gains/losses and FX remeasurement dominating GAAP revenue. Annual revenue is genuinely down from $21.55B (2021) to $17.36B (2025), a real -4% CAGR, but the quarterly volatility is largely noise. Underwriting premium is far more stable than these prints suggest, and the models keep treating this like a SaaS decel. The -33% recent earnings YoY and -23% forward EPS "collapse" in the thesis eval are almost certainly comparing against a quarter juiced by yen hedging gains or reserve releases. That matters because the entire bear thesis rests on numbers that aren't actually operational.
That said, the direction of travel is real: 2025 NI of $3.65B vs 2024's $5.44B is a meaningful step-down, ROE at 12.4% is unremarkable for a mature insurer, and the two most recent quarters (Q1/Q2 2026) at 23.4% and 20% margins are the lowest sustained margin regime in the dataset ex-2024Q3. Insider activity is unambiguous — six sales on 6/22 alone including a 23,416-share block, no offsetting buys, and a classic option-exercise-and-dump pattern. At $121 with 42 years of dividend increases and only a 2% yield, you're paying for the streak, not the cash flow. Operating CF of $2.56B against a $60.9B market cap is a 4.2% OCF yield — thin for something growing at negative 4%.
Where I part ways with the models: the synthesis fair value of $98-101 is anchored on a DCF that treats declining GAAP revenue as declining economics, which overstates the deterioration. The thesis eval's "distribution obsolescence" bear case (72 weight) is the right long-term worry but is not visible in the 2026 numbers — Aflac Japan's cancer/medical supplemental franchise isn't being disrupted by anything specific this cycle; it's just slowly shrinking with demographics. Conversely, the bull case's "yen recovery unlocks hidden earnings" is a coin flip masquerading as an edge — if you can't predict USD/JPY, you don't have a thesis, you have a bet. The narrative layer correctly identifies this as anchored/steady-compounder with moderate durability; I'd push durability lower given the insider selling cluster and the fact that P/B of 2.2x is rich for a 12% ROE insurer (fair P/B at 12% ROE and 9% cost of equity is ~1.3x, implying ~$72 on book value alone).
A careful contrarian would argue Aflac is a hedge, not an investment: it's one of the few large-cap US-listed proxies for a weaker yen reversing (i.e., stronger yen = higher translated Japan earnings), it has a fortress balance sheet with zero debt-to-equity and $6.25B cash, and dividend aristocrats structurally trade at premiums that don't mean-revert on DCF timelines because SCHD/VYM flows are price-insensitive. That's a real argument for why $121 can persist. But "can persist" isn't "should be bought" — the 2% yield is below the 10Y Treasury, the payout ratio at 33% leaves room to grow dividends but management has been growing them at only mid-single digits, and you're getting negative organic growth. I agree with the synthesis that fair value is closer to $95-105 than $121, but I'd dissent from the framing that the business is deteriorating rapidly — it's deteriorating slowly and being repriced from a premium that ETF flows built. The right entry is $95-100, not here. Insider selling into strength confirms management sees the same gap.
GPT Reading
At $121.45, Aflac looks expensive for what the actual numbers say is a shrinking, more volatile earnings stream. The annual picture is the first red flag: revenue has fallen from $21.55B in 2021 to $17.36B in 2025, a roughly 19% drop, while net income has not collapsed but has clearly become less dependable, moving from $5.44B in 2024 to $3.65B in 2025. That means the market is paying 17.8x trailing earnings and 2.2x book for a business with negative four-year revenue drift, low-teens ROE of 12.4%, and only a 2.0% dividend yield. Those are not distressed multiples, and they are not especially cheap “boring insurer” multiples either. They imply a steadier franchise than the reported quarterly data supports.
The quarterly pattern is even less flattering than the annual summary. Revenue was $5.40B in 4Q24, then dropped to $3.40B in 1Q25, recovered to $4.16B in 2Q25, $4.74B in 3Q25, $4.87B in 4Q25, then slid again to $4.35B in 1Q26 and $4.12B in 2Q26. That latest quarter is essentially flat with 2Q25 on revenue but net income jumped from $599M to $825M, which tells me the earnings line is being driven by investment and reserve noise more than by clean operating momentum. More importantly, the most recent YoY direction is bad: revenue down 9.3% and earnings down 33% on the provided momentum view. Aflac can survive volatility; insurers do. But the stock is not priced like a volatile, no-growth insurer. A $60.9B market cap against $29.5B equity means investors are still granting a very healthy franchise premium despite the fact that operating cash flow in 2025 was only $2.56B, well below net income of $3.65B, which is another reason I’m skeptical of taking headline EPS quality at face value.
What stands out to me is that the “mature earner” label is directionally right, but the market seems to be paying for maturity without demanding enough compensation for stagnation. If this were a classic cash-machine insurer with stable top line, stable underwriting, and mid-teens ROE, 17-18x earnings could be arguable. But here, annual revenue is lower than it was three and four years ago, quarterly margins have ranged from -3.2% to 35.2%, and the latest two quarters show net income of $1.02B then $825M, well below the late-2025 run rate. On simple math, a more appropriate multiple looks like 13-15x normalized earnings. Put that on $6.50-$7.00 of normalized EPS power implied by a $3.6-$4.0B earnings base on a $60.9B market cap and you get a valuation band more like $90-$105, not $121.
The best rebuttal is that Aflac is exactly the kind of franchise that screens optically expensive right before buybacks, capital return, and reserve stability make the valuation look reasonable again. Net income from 2021 to 2025 still averaged well above $4B despite all the messiness, the balance sheet shows $6.25B of cash and no debt in this snapshot, and the payout ratio at 32.9% leaves plenty of room for continued dividend growth. If you believe 2025’s $3.65B was a trough rather than a new base, then 2024’s $5.44B shows what earnings can look like when markets and FX cooperate. On that interpretation, 2.2x book is not crazy for a conservatively capitalized insurer with a long dividend record and decent 12%+ ROE, especially if share count reduction is doing a lot of the shareholder-return work outside this dataset. I weigh that less heavily because the burden should be on the bull case to show stabilization in reported revenue and cash conversion, and that evidence just is not here yet.
What would change my mind is straightforward: I’d want to see two things at once. First, a return to consistent quarterly earnings above $1.0B without relying on a collapsing revenue base, ideally with revenue holding at or above $4.5B for several quarters. Second, annual operating cash flow needs to move back toward or above net income rather than lagging it by over $1B. If Aflac can print something closer to a $4.5B-$5.0B annualized earnings run rate with steadier top-line conversion, then today’s price could be justified. Absent that, I think the stock is being granted a quality premium that the recent numbers do not earn.
Grok Reading
The raw numbers describe a franchise in managed decline, not a steady compounder. Annual revenue has slid from $21.55B in 2021 to $17.36B in 2025, a roughly 4% CAGR contraction that accelerated into the most recent print. Net income told a more flattering story through 2024’s $5.44B peak before collapsing to $3.65B in 2025; the last four reported quarters show the same pattern in miniature, with NI stepping down from $1.64B to $1.38B to $1.02B to $825M even as quarterly revenue hovered in a $4.1–4.9B band. Operating cash flow of only $2.56B against that $3.65B of reported earnings is the clearest quality flag in the set—nearly 30% of accounting profit failed to convert to cash. At $121.45 the stock trades 17.8× trailing earnings, 3.7× sales and 2.2× book on a 12.4% ROE; those multiples would be defensible for a mid-single-digit grower, not for a business whose earnings CAGR is –11.5% and whose recent year-over-year earnings drop is 33%. The 2.0% dividend yield and 33% payout are sustainable but ordinary compensation for a shrinking top line and negative free-cash-flow trajectory.
What the models label “mature earner” and “dividend-income” is accurate as far as it goes, yet the valuation synthesis’s $98–101 fair-value range (19% below the tape) is the more honest reading of the same data. Revenue volatility is not noise; it is the business. Japan still dominates earnings, U.S. worksite supplemental faces structural pressure from higher deductibles, and the balance sheet’s zero reported debt and $6.25B cash pile simply confirm that capital returns are the only remaining growth story. Insider activity in June 2026 was almost uniformly sales—more than 90,000 shares disposed across multiple filings—consistent with management treating the current multiple as full.
The strongest counter-argument is that insurance earnings are intentionally noisy and that the market is correctly capitalizing a durable underwriting franchise plus yen-translation optionality. A 12% ROE, fortress liquidity, 42-year dividend streak and sector-leader status can justify a mid-teens P/E even with flat premiums if cash generation remains predictable; the 2024 $5.44B NI year shows the earnings power still embedded in the book when investment marks cooperate. Bulls can also note that a 2.2× price-to-book multiple is not extreme for a clean balance sheet and that any sustained yen recovery would mechanically lift reported EPS without requiring operational improvement. Those points keep me from a table-pounding short, but they do not erase the multi-year contraction in revenue, earnings and cash flow that the price simply ignores.
I would reverse to neutral or better on two clean data points: trailing-twelve-month operating cash flow reclaiming $4B-plus, and two consecutive quarters of positive organic premium growth in both Japan and the U.S. Absent that, the stock remains a dividend vehicle priced as if the decline has already ended.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Aflac generates consistent underwriting profitability with net income of $3.65B-$5.44B over five years and free cash flow of $2.56B-$5.05B annually. The share count has been reduced from 662M to 535M (roughly 19% shrink over four years), a meaningful per-share value transfer to holders and a hallmark of disciplined capital return in a mature earner. Revenue, however, has drifted from $21.55B in 2021 to $17.36B in 2025 (down ~19%), and 2025 net income fell to $3.65B from $5.44B in 2024, signaling that the top-line and current-year earnings power are softening (yen translation and premium runoff are plausible drivers, but not confirmed here). OCF/NI at 0.79x is acceptable for an insurer where reserve movements distort accruals, though it is worth noting FCF has declined every year from $5.05B to $2.56B. The Altman Z of 1.22 flagged as distress is a false positive: the model is not calibrated for insurance balance sheets loaded with policy reserves and investment assets. Insider selling is dominated by Japan Post Holdings, a strategic partner unwinding its stake, not operating management dumping shares; the CFO Moskowitz sale is routine option-exercise-and-sell. Overall this reads as a well-run, capital-return-focused insurer with a real revenue/earnings softening trend rather than an integrity problem.
Verify before trusting this (5)
- Whether 2025 revenue/NI drop is FX (yen weakness) versus underlying premium runoff
- Reserve development and adequacy in US and Japan segments
- Investment portfolio credit quality and any unrealized loss position
- Buyback pace and remaining authorization
- Any 10-K disclosure on Japan Post relationship changes given the sell-down
The e2e composite pins fair value at $101.10 and the signal-adjusted FV at $98.17, both meaningfully below the $121.45 tape - an implied ~19-20% overpayment. The anchored-PE cross-check lands at the same $101 zone, so the methods corroborate rather than diverge; this isn't a runaway model. Layer on the weak earnings-quality haircut (OCF-to-NI slippage, 2025 EPS step-down, FCF roughly half of 2021) and deserved value drifts lower, not higher.
Verify before trusting this (4)
- Japan segment premium income trajectory and yen-hedge disclosures in the next 10-Q
- OCF vs net income reconciliation - is the slippage one-off reserve timing or structural
- Buyback pace and remaining authorization
- US supplemental new annualized premium growth - inflecting or still leaking
The macro tape is mildly risk-on with VIX at 14.3 and the S&P near highs, but AFL's 0.6 beta means the tailwind mostly bypasses this name. Meanwhile the stock is down 9.3% recently against a -4% longer trend, telling you the pressure on THIS ticker is idiosyncratic, not market-driven. The steady-compounder narrative is moderate/moderate with low cult - it has no story momentum to defend itself when sales disappoint. Q2 earnings drew a negative market reaction on a YoY sales decline, and the follow-up analyst framing ('stay invested for now', 'revealing questions') is the tepid, defensive tone you get when the story is quietly cracking rather than breaking. For a dividend-aristocrat insurer, that matters: these names trade on narrative durability, and the durability is being tested. Macro cross-currents are mixed but net negative for the name - higher rates help insurer investment income (mild tailwind) but the yen tailwind that props the bull thesis is fragile, and Japan demographic bear points are gaining airtime post-print. Net: a low-intensity but persistent headwind, more drift than shock.
Verify before trusting this (4)
- Whether analyst target revisions follow through negatively after the Q2 miss narrative
- Yen/dollar direction - a sharp yen strengthening would accelerate the headwind
- Any sector rotation into defensive insurers if the risk-on tape falters
- Whether U.S. supplemental sales stabilize in Q3 guidance
Aflac sells a promise backed by regulated capital, not an information service, so AI reaches it mainly through the cost side and the distribution layer: claims automation, underwriting triage, multilingual service and agent productivity lower unit administrative cost on a fixed-price contract, which is margin-accretive; the risk is not that AI writes better cancer policies but that AI agents sitting between employers, brokers and carriers turn supplemental cover into a price-shopped commodity, and that cheaper individual risk prediction sharpens adverse selection in simplified-issue products; neither mechanism explains the recent revenue decline, which is currency, pricing discipline and persistency, not AI.
None surfaced.
Verify before trusting this (8)
- RBC/SMR capital ratios
- Claims payment reputation metrics
- Regulatory capital rule changes
- US deductible/out-of-pocket trend
- Japan third-sector market size
- Employer benefit budget shifts
- Policyholder persistency rates
- Broker platform integrations
The world is moving toward higher-for-longer rates, which is a friend to a big fixed-income insurance balance sheet — reinvestment yields above the legacy book are the main reason earnings power can hold while premium does not grow. Against that, the two structural currents run the wrong way: Japan's population is shrinking and its third-sector market is saturated and fiercely contested by domestic carriers, so Aflac's dominant profit pool has no volume runway; and in the U.S., supplemental insurance sits inside employer benefit budgets that are being squeezed by medical trend, with distribution increasingly intermediated by brokers and benefit platforms that commoditize product choice. FX is the wild card that makes any single reported quarter nearly unreadable. Net: a durable, cash-generative franchise operating in a market that no longer expands for it — growth, if it appears, will come from spread income, margin and share count, not from more policyholders.
When we made this prediction on Aug 17, 2026, AFL was $121.45. We expect it to be $114.00 by Feb 2027, and we consider it great value under $100.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 17, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.